ArticleParasites & vectors2025
Efficacy of Simparica Trio® against induced infections of Ancylostoma braziliense and Ancylostoma ceylanicum in dogs.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHookworm infections such as Ancylostoma braziliense and A. ceylanicum pose a significant threat to pets and are implicated in causing zoonotic diseases. Despite the availability of preventatives, compliance can be lacking. Increasing pet owner options and combining endo- and ectoparasite treatments might improve this compliance. In four separate studies, we investigated the efficacy of Simparica Trio® (Zoetis Inc., Parsippany, NJ, USA) containing minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel against fourth- and fifth-stage larvae (L
methodsFour negatively controlled, randomised and blinded laboratory studies were conducted against induced infections of A. braziliense and A. ceylanicum, with the interval between infection and treatment selected to evaluate efficacy against each targeted stage. Each treated dog received a single oral dose of Simparica Trio® at the recommended label dose. Necropsy was conducted for worm recovery on day 7 or 8 post-treatment.
resultsNo treatment-related adverse events were recorded in any of the studies. No worms were recovered from any of the Simparica Trio®-treated dogs in all four studies, thus resulting in 100% efficacy (P ≤ 0.0005) of Simparica Trio® against all stages of A. braziliense and the adult stage of A. ceylanicum in dogs.
conclusionsSimparica Trio® containing sarolaner, moxidectin and pyrantel was highly effective against induced infections of L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.